Inclusion Criteria:

- Lack of suitable conventional donor (i.e. 7/8 or 8/8 related or 7/8 or 8/8 unrelated
donor) or presence of rapidly progressive disease not permitting time to identify an
unrelated donor

- HLA typing will be performed at high resolution (allele level) for the HLA-A, -B, Cw,
and DRBl, and loci. A minimum match of 5/10 is required. The donor and recipient
must be identical, as determined by high resolution typing, at least one allele of
each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, and HLA- DRB1.

- Subjects with adequate physical function as measured by:a)Cardiac: Left ventricular
ejection fraction at rest must be >35%, or shortening fraction > 25%. b)Hepatic:
Bilirubin < 2.5 mg/dL; and ALT, AST, and Alkaline Phosphatase < 5 x ULN. c)Renal:
Serum creatinine within normal range for age, or creatinine clearance or GFR > 40
mL/min/1.73m2. d)Pulmonary: FEV 1, FVC, DLCO (diffusion capacity) > 50% predicted
(corrected for hemoglobin); or 02 saturation > 92% on room air.

- Clinical Diagnosis of one of the following: Acute Lymphoblastic Leukemia, Acute
Myelogenous Leukemia, Lymphoma

- Subjects must have received cytotoxic chemotherapy within 3 months of consent date
(measured from the start date of chemotherapy).

- Performance status: Karnofsky/Lansky score > 60%.

Exclusion Criteria:

- HLA-matched, related or 7-or 8/8 allele matched (HLA-A,-B,-Cw,-DRBl) unrelated donor
able to donate.

- Autologous hematopoietic stem cell transplant < 3 months prior to enrollment.

- Pregnancy or breast-feeding.

- Evidence of HIV infection or known HIV positive serology.

- Current uncontrolled bacterial, viral or fungal infection (currently taking
medication with evidence of progression of clinical symptoms or radiologic findings).

- Non-hematologic malignancy within prior three (3) years.

- Prior allogeneic hematopoietic stem cell transplant.

- Subjects with a history of primary idiopathic myelofibrosis.

- Bovine product allergy.